Published Online:4 May 2012https://doi.org/10.2217/pme.12.13
Abstract
The pace of technical and scientific advancement for genomics-based technologies has outstripped the ability of the US regulatory bodies to keep abreast of the emerging paradigms, resulting in regulatory pronouncements that often appear dated and payment systems that are misaligned. Over burdensome evidentiary requirements, encroachment of federal regulators into the practice of laboratory medicine, and failure to align public health objectives with pay or valuation sufficient to support professional pathology services and necessary capital investment threaten to stifle continued innovation in genomic-based diagnostic tools. Nevertheless, the US FDA is committed to improving regulatory science and to increased stakeholder participation in policy-making, and serious efforts to address coding and test value are underway. Moreover, federal legislation will be debated in the coming months that, if enacted, could clarify authorities and institute meaningful regulatory and reimbursement paradigms better suited to molecular testing. This review explores these dynamic policy issues and their implications for genomic pathology as the foundation of personalized medicine.
Keywords:
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Hamermesh R, Aspinall M, Gordon R. The Explosion of Genetic Testing: Opportunities and Challenges. Harvard Business School N1-810-067, 9 November (2009).
- 2 US Federal Food, Drug and Cosmetic Act. Section 201(h).
- 3 21 CFR 809.3(a).
- 4 21 U.S.C . § 301 et s∼.▪ Some stakeholders have questioned whether the US FDA has the authority under the Federal Food, Drug and Cosmetic Act to regulate laboratory-developed tests, including those that are discussed herein. This Article takes no position on the FDA’s claim to such legal authority.
- 5 21 CFR 809.10 (c)(2)(i).▪ FDA guidance on the definition of research use only (RUO) products.
- 6 21 CFR Part 812 (21 CFR 812.2(c).▪ FDA guidance on the definition of RUO products.
- 7 21 CFR 812.2(c)(3)(iv).▪ FDA guidance on the definition of RUO products.
- 8 H.R. 2307 (Introduced by Representative Michael Burgess on 14 October 2011).
- 9 Institute of Medicine. Medical Devices and the Public’s Health: The FDA 510(k) Clearance Process at 35 Years. The National Academies Press, Washington, DC, USA (2011).
- 10 21 CFR 807.92(a)(3).
- 11 US FDA Public Workshop on Laboratory Developed Tests. 19–20 July 2010, College Park, MD USA.
- 12 Open Meeting on the Oversight of Laboratory Developed Tests. 22 November 2010, Grand Hyatt Hotel, Washington, DC, USA.
- 13 5 U.S.C. § 553; 21 cfr 10.115(b)(1).▪ See Administrative Procedure Act, requiring notice and comment on rulemaking.
- 14 Republicans on the House Energy and Commerce Committee Friday released an FDA reform legislative package, including a bill that would prevent the agency from regulating laboratory-developed tests (LDTs) BioCentury Extra 14 October (2011).
- 15 Medical Device User Fee and Modernization Act (MDUFMA), P.L. 107–250. Amendment to the US Federal Food, Drug and Cosmetic Act. 26 October 2002.
- 16 The Prescription Drug User Fee Act (PDUFA) was enacted in 1992 and renewed in 1997 (PDUFA II), 2002 (PDUFA III), and 2007 (PDUFA IV).
- 17 Hamburg MA, Collins FS. The Path to Personalized Medicine. N. Engl. J. Med.363, 301–304 (2010).
- 18 FDA Notice of Public Meeting on Oversight of Laboratory Developed Tests, Federal Register. 75(116), 34463–34464, 17 June (2010).
- 19 Tezak Z. FDA-industry IVD Roundtable Meeting. 13 January 2010 Silver Spring, MD, USA.
- 20 Hamburg M. America’s Innovation Agency: The FDA, By instilling confidence in US products and technologies, we stimulate economic growth and open markets overseas. New York Times 1 August (2011).
- 101 Ray T. FDA’s Woodcock says personalized drug development entering ‘long slog’ phase. Pharmacogenomics Reporter (2011). www.genomeweb.com/print/982752
- 102 Swanson J. Companion diagnostics take off. Genome Technology (October 2009). www.genomeweb.com/dxpgx/companion-diagnostics-take
- 103 FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. FDA Newsroom, 17 August 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm
- 104 FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer, FDA Newsroom, 17 August 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm
- 105 Department of Health and Human Services, FDA, Docket No. FDA-2010-N-0274, Oversight of Laboratory Developed Tests. http://www.regulations.gov/#!searchResults;rpp=25;po=0;s=fda-2010-N-0274
- 106 Dr Elias Zerhouni, Former Director, NIH describing the objectives of the new NIH Roadmap for Medical Research. September 2004. http://commonfund.nih.gov/aboutroadmap.aspx
- 107 Accelerating products from the science lab to the marketplace, in a White House Blog, ‘Lab to Market’ initiatives transforming new ideas into new Jobs. 28 October 2011. www.whitehouse.gov/blog/2011/10/28/lab-market-initiatives-transfrming-new-ideas-new-jobs
- 108 European Commission. Recast of the medical devices directives: public consultation. http://ec.europa.eu/consumers/sectors/medical-devices/files/recast_docs_2008/public_consultation_en.pdf
- 109 European Commission, consumer affairs. Revision of the medical devices directives: 2008 – onwards. http://ec.europa.eu/consumers/sectors/medical-devices/documents/revision/index_en.htm
- 110 European Commission, recast of the medical devices directives: public consultation. http://ec.europa.eu/consumers/sectors/medical-devices/files/recast_docs_2008/public_consultation_en.pdf
- 111 US FDA product code for LDTs. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/PCDSimpleSearch.cfm?db=PCD&id=OQS▪ The FDA’s informal definition of laboratory-developed tests, which currently account for much of clinical laboratory analysis performed in support personalized medicine.
- 112 Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents: Frequently Asked Questions. 14 September 2007. www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071269.pdf
- 113 FDA drafts regulatory guidance to industry and labs for group of medical tests, FDA Newsroom, Press Release. 5 September 2006. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108726.htm
- 114 Draft guidance for industry, clinical laboratories, and FDA staff – In vitro Diagnostic Multivariate Index Assays. 26 July 2007. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm079148.htm
- 115 Comments on the FDA docket on proposed FDA regulation of LDTs by Genetic Alliance, Coalition for 21st Century Medicine, and American Clinical Laboratory Association. www.regulations.gov/#!docketDetail;dct=PS;rpp=25;po=0;D=FDA-2010-N-0274
- 116 FDA warning letter on OvaSure. www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048114.htm
- 117 The Coalition for 21st Century Medicine. www.twentyfirstcenturymedicine.org
- 118 Ray T. Latest draft of Hatch IVD Bill contains new regulatory proposals; pricing reforms under discussion. Pharmacogenomics Reporter. 6 July 2011. www.genomeweb.com/print/973340
- 119 Citizen Petition filed by Genentech, Inc., Dkt. No. FDA-2008-P-0638-001 (filed 8 December 2008). www.regulations.gov/#!documentDetail;D=FDA-2008-P-0638-0001.
- 120 Additional Public Comments by IVD Manufacturers and other stakeholders regarding FDA oversight of LDT. www.regulations.gov/#!searchResults;rpp=10;po=0;s=FDA-2008-P-0638
- 121 Transcript, US Department of Health and Human Services, FDA, public meeting on oversight of laboratory develop tests, 19 July 2010, Joshua Sharfstein, MD, Principal Deputy Commissioner, FDA. www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM226203.pdf
- 122 Open Meeting on the Oversight of Laboratory Developed Tests, 22 November 2010, Grand Hyatt Hotel, Washington, DC, USA, Avalere Health LLC. www.acla.com/sites/default/files/20101215_AvalereSummaryLDT_v2.pdf
- 123 FDA regulatory science plan positions agency to foster innovation through better science, FDA Press Release. 17 August 2001. www.fda.gov/newsevents/newsroom/pressannouncements/ucm268293.htm
- 124 Guidance for Industry and FDA Staff -510(k) Device Modifications: deciding when to submit a 510(k) for a change to an existing device. 29 July 2011. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm265274.htm
- 125 Pathway to FDA medical device approval: is there a better way? Statement of Jeffrey Shuren, MD, JD, Director FDA-CDRH, before the Subcommittee on Healthcare, District of Columbia, Census and the National Archives Committee on Oversight and Government Reform US House of Representatives. 2 June 2011. www.fda.gov/NewsEvents/Testimony/ucm256062.htm▪ Provides insight into the issues surrounding 510(k) submissions from the FDA’s perspective.
- 126 Javitt G, Carner K. Must FDA engage in rulemaking to regulate laboratory-developed tests? Food and Drug Law Institute Policy Forum, 1(17), 14 September (2011). www.sidley.com/files/Publication/d83df2d8-e7a8-4159-8cff-57bc99413ebe/Presentation/PublicationAttachment/9ab25938-f024-4f9d-9535-58be237fd31f/FDLI%20Policy%20Forum%2017.pdf▪ Guidance documents cannot, as a matter of law, “create or confer any rights for or on any person” (citing 21 USC Sec. 371[h][1][A]).
- 127 H.R. 3207, 14 October 2011. www.opencongress.org/bill/112-h3207/show
- 128 Back to school issue: innovation & collaboration. BioCentury 19(3), Page A6 of 2. (2011). www.biocentury.com/biotech-pharma-news/coverstory/2011-09-05/how-biopharma-government-academia-must-partner-a1
- 129 Documents the Center for Devices and Radiological Health is Considering for Development (FY12), Framework for Regulatory Oversight of Laboratory Developed Tests. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/MedicalDeviceUserFeeandModernizationActMDUFMA/ucm109196.htm
- 130 Draft guidance for industry and FDA – In vitro companion diagnostic devices. 14 July 2011. www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm▪ An important document on the emerging paradigm of so-called companion diagnostics.
- 131 FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer, FDA Newsroom. 17 August 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm
- 132 Guidance for industry, E16 biomarkers related to drug or biotechnology product development: context, structure and format of qualification submissions. 10 August 2011. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM267449.pdf
- 133 Draft guidance for industry and FDA staff – factors to consider when making benefit–risk determinations in medical device premarket review. 15 August 2011. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm267829.htm
- 134 Draft guidance for industry and FDA staff – De Novo Classification Process (Evaluation of Automatic Class III Designation). www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm273902.htm
- 135 Draft guidance for industry and FDA staff – commercially distributed in vitro diagnostic products labeled for research use only or investigational use only: frequently asked questions. 1 June (2011). www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm253307.htm▪▪ FDA guidance on the use of reagents labeled research use only or investigational use only in laboratory-developed tests; this document has generated considerable uncertainty with respect to clinical testing in the field of personalized medicine.
- 136 CMS directs expansion of the molecular diagnostics services (MolDx) program. 4 November 2011. www.palmettogba.com/palmetto/providers.nsf/DocsCat/Jurisdiction%201%20Part%20B∼Articles∼ MolDx∼General∼CMS%20Directs%20Expansion%20of%20the%20Molecular%20Diagnostic%20Services% 20(MolDx)%20Program (Accessed 4 November 2011)
- 137 Molecular diagnostic services program (MolDX) test registry process. www.palmettogba.com/palmetto/providers.nsf/vMasterDID/8NLQ3C5314?OpenDocument
